摘要
目的:在化疗早期根据肿瘤对平阳霉素的反应,判断平阳霉素对口腔鳞癌的疗效,使对平阳霉素效果差 的患者尽早停止化疗,以减少毒副反应的发生。方法:从本院近16年来接受平阳霉素化疗的病例中,筛选出接受平 阳霉素治疗前未接受过化疗或放疗的 73例患者,按 WHO疗效标准,分为有效组(38例)与无效组(35例)。首先确定 每个样本的最低显效剂量(肿瘤或溃疡开始缩小的平阳霉素累计用量),求其均数和标准差(x±s),然后以此作为样 本的最低显效剂量,确定每个样本在该剂量时是否开始显效,并时两组进行χ2检验。两组的最终剂量用t检验进行 分析。结果:1)两组的最终剂量无显著性差异(P>0.05)。2)平阳霉素对口腔鳞癌化疗的最低显效剂量59±18mg,在此 剂量显效的患者,随剂量增加,疗效逐渐明显。在此剂量未显效的患者,随剂量增加,多数未出现疗效(P<0.01)。结 论:59±18mg可作为平阳霉素对口腔鳞癌化疗疗效的筛选剂量。
Objective To assess the response to pingyangmycin in patients with oral squamous cell carcinoma in early stage of preoperative chemotherapy. Methods: A total of 73 cases of oral squamous cell carcinoma previously untreated which received preoperative chemotherapy of pingyangmycin were divided into two groups: responders (CR+PR: 38 cases) and non-responders (SD+PD: 35 cases). After making sure of the minimal effective dose of every case and deciding whether the tumor size of every case reduced at the minimal effective dose (mean +SD). The statistic analysis was done between these two groups. Results: 1) The total dose of these two groups had no significant difference (P>0.05). 2) The cases of which tumor size had reduced at the minimal effective dose (59mg±18mg) usually had good response (P<0.01). Conclusion: Whether the tumor size reduced at the minimal effective dose may be a predictor of responsiveness to pingyangmycin in patients with oral squamous cell carcinoma.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2001年第3期204-206,共3页
Chinese Journal of Clinical Oncology
关键词
平阳霉素
最低显效剂量
口腔鳞癌
药物治疗
Pingyangmycin Minimal effective dose Oral squamous cell carcinoma